BACKGROUND: Reported relapse and recurrence rates in bipolar disorder (BD) differ significantly between studies. Most data originate from highly selective patients participating in sponsored randomized controlled trials with narrow inclusion criteria. To estimate the true risk of a subsequent mood episode (SME) under real-world conditions, we conducted a meta-analysis of rates of SME as reported in naturalistic BD studies. METHODS: PubMed, ScienceDirect, Scopus, and Web of Knowledge were searched until July 2015. Studies reporting the time until the emergence of an SME, from which individual data or Kaplan-Meier plots with censors marked could be retrieved, were included. RESULTS: Twelve studies comprising 5,837 patients met the inclusion criteria. The median time to an SME in adults after an index episode was 1.44 years. The risk of an SME was 44% during the first year. Not having a SME during this first year lowered this risk to 19% in the second year. The risk was higher in bipolar II disorder (BD-II) than in bipolar I disorder (BD-I; HR = 1.5). In BD-I, the risk of a subsequent manic, mixed, or depressive mood episode was higher after an index episode of the same polarity (HR = 1.89-5.14). The overall risk of an SME was higher in patients with persisting subsyndromal symptoms (HR = 2.17). CONCLUSIONS: The data from this study provide a more reliable estimate of the risk of an SME in BD in real-world settings. Further research into the longitudinal course of BD-II is warranted to confirm its role as a risk factor for SME.
BACKGROUND: Reported relapse and recurrence rates in bipolar disorder (BD) differ significantly between studies. Most data originate from highly selective patients participating in sponsored randomized controlled trials with narrow inclusion criteria. To estimate the true risk of a subsequent mood episode (SME) under real-world conditions, we conducted a meta-analysis of rates of SME as reported in naturalistic BD studies. METHODS: PubMed, ScienceDirect, Scopus, and Web of Knowledge were searched until July 2015. Studies reporting the time until the emergence of an SME, from which individual data or Kaplan-Meier plots with censors marked could be retrieved, were included. RESULTS: Twelve studies comprising 5,837 patients met the inclusion criteria. The median time to an SME in adults after an index episode was 1.44 years. The risk of an SME was 44% during the first year. Not having a SME during this first year lowered this risk to 19% in the second year. The risk was higher in bipolar II disorder (BD-II) than in bipolar I disorder (BD-I; HR = 1.5). In BD-I, the risk of a subsequent manic, mixed, or depressive mood episode was higher after an index episode of the same polarity (HR = 1.89-5.14). The overall risk of an SME was higher in patients with persisting subsyndromal symptoms (HR = 2.17). CONCLUSIONS: The data from this study provide a more reliable estimate of the risk of an SME in BD in real-world settings. Further research into the longitudinal course of BD-II is warranted to confirm its role as a risk factor for SME.
Authors: Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli Journal: World Psychiatry Date: 2018-06 Impact factor: 49.548
Authors: Lisa Ferrand; Vincent Hennion; Ophelia Godin; Frank Bellivier; Jan Scott; Bruno Etain Journal: J Clin Med Date: 2022-04-14 Impact factor: 4.964
Authors: Ulrike Stentzel; Neeltje van den Berg; Kilson Moon; Lara N Schulze; Josephine Schulte; Jens M Langosch; Wolfgang Hoffmann; Hans J Grabe Journal: BMC Psychiatry Date: 2021-06-29 Impact factor: 3.630
Authors: Boris Birmaher; John A Merranko; Mary Kay Gill; Danella Hafeman; Tina Goldstein; Benjamin Goldstein; Heather Hower; Michael Strober; David Axelson; Neal Ryan; Shirley Yen; Rasim Diler; Satish Iyengar; Michael W Kattan; Lauren Weinstock; Martin Keller Journal: J Am Acad Child Adolesc Psychiatry Date: 2020-01-21 Impact factor: 8.829
Authors: Caterina Del Mar Bonnín; María Reinares; Anabel Martínez-Arán; Esther Jiménez; Jose Sánchez-Moreno; Brisa Solé; Laura Montejo; Eduard Vieta Journal: Int J Neuropsychopharmacol Date: 2019-08-01 Impact factor: 5.176